Conestoga Capital Advisors LLC Has $155.98 Million Stock Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Conestoga Capital Advisors LLC lowered its holdings in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 14.4% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,692,834 shares of the medical instruments supplier’s stock after selling 285,517 shares during the period. LeMaitre Vascular makes up about 2.1% of Conestoga Capital Advisors LLC’s holdings, making the stock its 17th biggest position. Conestoga Capital Advisors LLC owned 7.53% of LeMaitre Vascular worth $155,978,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. DF Dent & Co. Inc. raised its stake in LeMaitre Vascular by 26.2% during the 3rd quarter. DF Dent & Co. Inc. now owns 258,767 shares of the medical instruments supplier’s stock worth $24,037,000 after buying an additional 53,797 shares during the period. Rice Hall James & Associates LLC increased its stake in LeMaitre Vascular by 15.7% in the 3rd quarter. Rice Hall James & Associates LLC now owns 261,306 shares of the medical instruments supplier’s stock valued at $24,273,000 after buying an additional 35,383 shares during the last quarter. F M Investments LLC boosted its stake in shares of LeMaitre Vascular by 36.6% in the 3rd quarter. F M Investments LLC now owns 123,545 shares of the medical instruments supplier’s stock worth $11,476,000 after buying an additional 33,087 shares during the last quarter. Barclays PLC lifted its holdings in LeMaitre Vascular by 394.5% during the third quarter. Barclays PLC now owns 36,577 shares of the medical instruments supplier’s stock worth $3,396,000 after acquiring an additional 29,180 shares during the period. Finally, State Street Corp grew its stake in LeMaitre Vascular by 3.6% in the 3rd quarter. State Street Corp now owns 822,085 shares of the medical instruments supplier’s stock valued at $76,363,000 after purchasing an additional 28,525 shares during the period. 84.64% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction on Friday, November 15th. The shares were sold at an average price of $101.47, for a total transaction of $380,512.50. Following the transaction, the director now owns 2,278 shares of the company’s stock, valued at approximately $231,148.66. This trade represents a 62.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 10.79% of the company’s stock.

LeMaitre Vascular Trading Down 3.2 %

LMAT stock opened at $96.93 on Monday. LeMaitre Vascular, Inc. has a 1-year low of $56.61 and a 1-year high of $109.58. The stock has a market cap of $2.18 billion, a price-to-earnings ratio of 52.97, a price-to-earnings-growth ratio of 2.13 and a beta of 0.96. The company’s 50 day moving average is $97.41 and its 200 day moving average is $92.94.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. The company had revenue of $54.82 million during the quarter, compared to the consensus estimate of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The firm’s revenue was up 15.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.33 EPS. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on LMAT shares. Cantor Fitzgerald initiated coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 price target for the company. Oppenheimer reaffirmed an “outperform” rating and set a $93.00 price target (up previously from $90.00) on shares of LeMaitre Vascular in a research report on Friday, November 1st. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Barrington Research boosted their price target on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a research report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $94.57.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.